11. Priporočila za obravnavo bolnic z rakom jajčnikov, jajcevodov in s primarnim peritonealnim seroznim rakom v SlovenijiNina Kovačević, 2022, ni določena Ključne besede: serozni rak, diagnostika, sledenje pacientov, recidiv, epidemiologija, histopatologija, kirurško zdravljenje, sistemsko zdravljenje, radioterapija, gensko svetovanje, zdravstvena obravnava, smernice, zborniki
Objavljeno v DiRROS: 10.11.2022; Ogledov: 709; Prenosov: 194
 Celotno besedilo (397,45 KB) |
12. 3. šola o sarkomih : Mezenhimski tumorji maternice2022, ni določena Ključne besede: rak (medicina), multidisciplinarna obravnava, klasifikacija, diagnostika, patološka histologija, kirurško zdavljenje, biološko zdravljenje, sistemsko zdravljenje, radioterapija, sledenje pacientov, zborniki
Objavljeno v DiRROS: 09.11.2022; Ogledov: 703; Prenosov: 323
Celotno besedilo (4,12 MB)
Gradivo ima več datotek! Več... |
13. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer : an international multicenter studyZsolt Megyesfalvi, Nandor Barany, Andras Lantos, Zsuzsanna Valko, Orsolya Pipek, Christian Lang, Anna Schwendenwein, Felicitas Oberndorfer, Sandor Paku, Bence Ferencz, Izidor Kern, Mile Kovačević, Viktoria Laszlo, Balazs Dome, 2022, izvirni znanstveni članek Povzetek: The tissue distribution and prognostic relevance of subtype-specific proteins (ASCL1, NEUROD1, POU2F3, YAP1) present an evolving area of research in small cell lung cancer (SCLC). The expression of subtype-specific transcription factors and P53 and RB1 proteins were measured by immunohistochemistry (IHC) in 386 surgically resected SCLC samples. Correlations between subtype-specific proteins and in vitro efficacy of various therapeutic agents were investigated by proteomics and cell viability assays in 26 human SCLC cell lines. Besides SCLC-A (ASCL1-dominant), SCLC-AN (combined ASCL1/NEUROD1), SCLC-N (NEUROD1-dominant) and SCLC-P (POU2F3-dominant), IHC and cluster analyses identified a quadruple-negative SCLC subtype (SCLC-QN). No unique YAP1-subtype was found. The highest overall survival rates were associated with non-neuroendocrine subtypes (SCLC-P and SCLC-QN) and the lowest with neuroendocrine subtypes (SCLC-A, SCLC-N, SCLC-AN). In univariate analyses, high ASCL1 expression was associated with poor prognosis and high POU2F3 expression with good prognosis. Notably, high ASCL1 expression influenced survival outcomes independently of other variables in a multivariate model. High POU2F3 and YAP1 protein abundances correlated with sensitivity and resistance to standard-of-care chemotherapeutics, respectively. Specific correlation patterns were also found between the efficacy of targeted agents and subtype-specific protein abundances. In conclusion, we have investigated the clinicopathological relevance of SCLC molecular subtypes in a large cohort of surgically resected specimens. Differential IHC expression of ASCL1, NEUROD1 and POU2F3 defines SCLC subtypes. No YAP1-subtype can be distinguished by IHC. High POU2F3 expression is associated with improved survival in a univariate analysis, whereas elevated ASCL1 expression is an independent negative prognosticator. Proteomic and cell viability assays of human SCLC cell lines reveal distinct vulnerability profiles defined by transcription regulators.
Ključne besede: Non-small-cell lung carcinoma, immunohistochemistry, molecular subtypes, prognostic relevance, expression pattern, neuroendocrine subtypes
Objavljeno v DiRROS: 27.05.2022; Ogledov: 1041; Prenosov: 1311
Celotno besedilo (4,37 MB)
Gradivo ima več datotek! Več... |
14. |
15. |
16. Klinična pot celostne rehabilitacije bolnikov z rakom dojkeNikola Bešić, Simona Borštnar, Vesna Homar, Denis Mlakar-Mastnak, Zlatka Mavrič, Anamarija Mozetič, Jana Knific, Nataša Kos, Nina Kovačević, Nada Rotovnik-Kozjek, Nena Kopčavar Guček, Mateja Kurir-Borovčić, Tanja Marinko, Ana Pekle-Golež, Irena Rahne Otorepec, Gabrijela Simetinger, Andreja Cirila Škufca Smrdel, Branka Stražišar, Tanja Španić, Lorna Zadravec-Zaletel, 2021, končno poročilo o rezultatih raziskav Ključne besede: rak dojke, bolniki, celostna rehabilitacija, klinične poti
Objavljeno v DiRROS: 14.03.2022; Ogledov: 947; Prenosov: 426
Celotno besedilo (2,09 MB)
Gradivo ima več datotek! Več... |
17. Rak jajčnikov : česa še ne vemo? : ginekološki simpozij : Ljubljana, 2. 12. 2021 : zbornik znanstvenih prispevkov2021, zbornik strokovnih ali nerecenziranih znanstvenih prispevkov na konferenci Povzetek: Ginekološki simpozij Rak Jajčnika: Česa še ne vemo? zajema sklop predavanj, kjer so predstavljeni začetna obravnava žensk s tumorji v področju jajčnikov, nadaljnja predoperativna priprava, najradikalnejši kirurški posegi in zadnje smernice na področju sistemske terapije. Prav tako pozornost namenjamo tudi stereotaktičnemu obsevanju in imunoterapiji, ki na področju ginekoloških rakov počasi dobiva svojo veljavo in mesto.
Ključne besede: napredovali rak, mejno maligni tumorji, ekstraabdominalna kirurgija, citoredukcija, bevacizumab, polimorbidnost, stereotaktično obsevanje, imunoterapija, zborniki, elektronske knjige
Objavljeno v DiRROS: 10.03.2022; Ogledov: 831; Prenosov: 387
Celotno besedilo (1,31 MB)
Gradivo ima več datotek! Več... |
18. Immunotherapy for metastatic non-small cell lung cancer : real-world data from an academic Central and Eastern European centerMarija Ivanović, Lea Knez, Ana Herzog, Mile Kovačević, Tanja Čufer, 2021, izvirni znanstveni članek Povzetek: Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
Ključne besede: non-small cell lung carcinoma, immunotherapy, advanced non-small cell lung cancer, real-world data, Central Europe, Europe, Eastern Europe
Objavljeno v DiRROS: 12.10.2021; Ogledov: 1062; Prenosov: 327
 Povezava na datoteko |
19. |
20. Sodobni pristop k obravnavi bolnic z rakom jajčnikov : 6. Šola o ginekološkem raku : elektronski zbornik prispevkov2021, ni določena Ključne besede: epidemiologija, tumorski označevalci, histopatologija, limfadenektomija, kemoterapija, sistemsko zdravljenje, radioterapija, ultraradikalna kirurgija, genetsko testiranje, molekularna diagnostika, zborniki, elektronske knjige
Objavljeno v DiRROS: 07.06.2021; Ogledov: 1309; Prenosov: 847
Celotno besedilo (34,17 MB)
Gradivo ima več datotek! Več... |
